Loading...
Market
Public Response to ADA-SCID Gene Therapy Approval/Rejection
4
Resolution / Starting Odds
Highly Positive • 25%
Somewhat Positive • 25%
Neutral • 25%
Negative • 25%
Surveys, public opinion polls, or major UK health forums
Story
UK Hospital, Led by Dr. Booth, Seeks ADA-SCID Gene Therapy Approval
Apr 25, 2024, 07:37 PM
A UK hospital is taking an unprecedented step to seek approval for an ADA-SCID gene therapy, a rare disease, after many biopharma companies have abandoned similar efforts. This initiative, led by Dr. Booth, marks a significant shift from traditional pharmaceutical company applications to a hospital-led approach. The move has sparked discussions about the NHS's systems for approving new medicines, with criticism from Tanya Curry, CEO of the Motor Neurone Disease Association, who stated, 'It’s appalling that people with a particular genetic subtype of motor neurone disease face being denied what could be a life-changing treatment because of the NHS’s outdated systems for approving new medicine.'
View original story
Similar markets
Highly Favorable • 25%
Somewhat Favorable • 25%
Somewhat Unfavorable • 25%
Highly Unfavorable • 25%
Strongly Oppose • 25%
Somewhat Oppose • 25%
Somewhat Support • 25%
Strongly Support • 25%
Predominantly positive • 33%
Predominantly negative • 33%
Mixed reactions • 34%
Mostly positive • 25%
Mixed reactions • 25%
Mostly negative • 25%
Indifferent or unaware • 25%
Strongly approve • 25%
Somewhat approve • 25%
Somewhat disapprove • 25%
Strongly disapprove • 25%
Highly Approved • 33%
Moderately Approved • 34%
Disapproved • 33%
Approval • 33%
Request for additional data • 33%
Rejection • 33%
Mostly positive • 33%
Mostly negative • 33%
Neutral • 34%
Broad support for continuation • 33%
Mixed reactions • 34%
Broad criticism leading to halt • 33%
Mostly positive • 33%
Mixed reactions • 33%
Mostly negative • 33%
Mostly favorable • 25%
Mixed reactions • 25%
Mostly unfavorable • 25%
No significant opinion • 25%
Mostly Positive • 33%
Neutral • 34%
Mostly Negative • 33%